Cardlytics, Inc. (NASDAQ:CDLX – Get Free Report) has been given an average recommendation of “Hold” by the seven brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $6.92.
A number of research firms recently commented on CDLX. Lake Street Capital lowered Cardlytics from a “buy” rating to a “hold” rating and lowered their price target for the company from $18.00 to $5.00 in a research report on Thursday, August 8th. Bank of America lowered shares of Cardlytics from a “neutral” rating to an “underperform” rating and dropped their price target for the company from $4.00 to $3.50 in a research report on Thursday, August 15th. Craig Hallum raised shares of Cardlytics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 6th. Evercore ISI began coverage on shares of Cardlytics in a research report on Friday, October 11th. They set an “in-line” rating and a $4.00 target price on the stock. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Cardlytics in a report on Thursday, November 7th.
Get Our Latest Research Report on Cardlytics
Insider Activity
Institutional Investors Weigh In On Cardlytics
Institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in shares of Cardlytics by 2.7% in the first quarter. Vanguard Group Inc. now owns 2,211,595 shares of the company’s stock valued at $32,046,000 after purchasing an additional 57,805 shares during the period. Geode Capital Management LLC raised its holdings in Cardlytics by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,053,178 shares of the company’s stock valued at $3,371,000 after acquiring an additional 73,484 shares during the period. Marshall Wace LLP lifted its position in shares of Cardlytics by 6.8% during the second quarter. Marshall Wace LLP now owns 814,281 shares of the company’s stock worth $6,685,000 after acquiring an additional 52,081 shares in the last quarter. RBF Capital LLC boosted its holdings in shares of Cardlytics by 311.9% in the third quarter. RBF Capital LLC now owns 488,128 shares of the company’s stock worth $1,562,000 after acquiring an additional 369,620 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Cardlytics by 3.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 390,343 shares of the company’s stock valued at $1,249,000 after purchasing an additional 11,388 shares in the last quarter. 68.10% of the stock is owned by hedge funds and other institutional investors.
Cardlytics Stock Up 3.4 %
Cardlytics stock opened at $3.93 on Friday. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 2.40. The firm’s fifty day moving average price is $3.74 and its two-hundred day moving average price is $6.14. The firm has a market capitalization of $199.73 million, a price-to-earnings ratio of -0.64 and a beta of 1.61. Cardlytics has a 1-year low of $2.89 and a 1-year high of $20.52.
Cardlytics (NASDAQ:CDLX – Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.18. The business had revenue of $67.06 million during the quarter, compared to the consensus estimate of $57.77 million. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. The company’s quarterly revenue was down 15.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.26) EPS. On average, equities research analysts predict that Cardlytics will post -1.52 earnings per share for the current fiscal year.
About Cardlytics
Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.
Featured Stories
- Five stocks we like better than Cardlytics
- Trading Stocks: RSI and Why it’s Useful
- Tesla Investors Continue to Profit From the Trump Trade
- Investing in Travel Stocks Benefits
- MicroStrategy’s Stock Dip vs. Coinbase’s Potential Rally
- What Does Downgrade Mean in Investing?
- Netflix Ventures Into Live Sports, Driving Stock Momentum
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.